Progesterone as an Anti-Inflammatory Drug and Immunomodulator: New Aspects in Hormonal Regulation of the Inflammation

The specific regulation of inflammatory processes by steroid hormones has been actively studied in recent years, especially by progesterone (P-4) and progestins. The mechanisms of the anti-inflammatory and immunomodulatory P-4 action are not fully clear. The anti-inflammatory effects of P-4 can be defined as nonspecific, associated with the inhibition of NF-kappa B and COX, as well as the inhibition of prostaglandin synthesis, or as specific, associated with the regulation of T-cell activation, the regulation of the production of pro- and anti-inflammatory cytokines, and the phenomenon of immune tolerance. The specific anti-inflammatory effects of P-4 and its derivatives (progestins) can also include the inhibition of proliferative signaling pathways and the antagonistic action against estrogen receptor beta-mediated signaling as a proinflammatory and mitogenic factor. The anti-inflammatory action of P-4 is accomplished through the participation of progesterone receptor (PR) chaperones HSP90, as well as immunophilins FKBP51 and FKBP52, which are the validated targets of clinically approved immunosuppressive drugs. The immunomodulatory and anti-inflammatory effects of HSP90 inhibitors, tacrolimus and cyclosporine, are manifested, among other factors, due to their participation in the formation of an active ligand-receptor complex of P-4 and their interaction with its constituent immunophilins. Pharmacological agents such as HSP90 inhibitors can restore the lost anti-inflammatory effect of glucocorticoids and P-4 in chronic inflammatory and autoimmune diseases. By regulating the activity of FKBP51 and FKBP52, it is possible to increase or decrease hormonal signaling, as well as restore it during the development of hormone resistance. The combined action of immunophilin suppressors with steroid hormones may be a promising strategy in the treatment of chronic inflammatory and autoimmune diseases, including endometriosis, stress-related disorders, rheumatoid arthritis, and miscarriages. Presumably, the hormone receptor- and immunophilin-targeted drugs may act synergistically, allowing for a lower dose of each.

Automated summary

The specific regulation of inflammatory processes by steroid hormones, particularly progesterone and progestins, has been actively studied in recent years. The anti-inflammatory effects of progesterone involve the inhibition of NF-kappa B and COX, as well as the regulation of T-cell activation, cytokine production, and immune tolerance. Progesterone and its derivatives can also inhibit proliferative signaling pathways and counteract proinflammatory signaling mediated by estrogen receptor beta. The anti-inflammatory action is mediated by progesterone receptor chaperones HSP90, FKBP51, and FKBP52. Drugs targeting these molecules, such as HSP90 inhibitors, can restore the lost anti-inflammatory effect of glucocorticoids and progesterone in chronic inflammatory and autoimmune diseases.